Evidence hub

Long COVID: cell-therapy evidence by therapy class

Across every stem-cell intervention, ClinicalTrials.gov holds 10 registered records for Long COVID — 2 recruiting, 1 at Phase 3 or 4, in 2 countries. Snapshot 2026-08-29.

Medical review statusMedically reviewedReviewed by: Stem Plus medical teamReviewed on: 2026-08-29Last evidence update: 2026-08-29Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

The condition, and why cells are proposed

Long COVID is a heterogeneous post-viral syndrome spanning autonomic dysfunction, exercise intolerance and cognitive symptoms, with no accepted biomarker. Cell rationales target persistent inflammation and endothelial dysfunction. Heterogeneity is the central research problem: several distinct conditions are probably being studied under one label.

Therapy classes side by side

Therapy classRegisteredRecruitingPhase 3/4Countries
MSC8102
HSCT0000
exosomes1001
PRP0000

Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.

Geography of the research

United States accounts for about 62% of country mentions among sampled studies; 2 countries host at least one site.

CountryStudies with a site there
United States5
China3

The largest registered studies

Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.

StudyPhaseStatusPlanned nLead sponsorStart
NCT06441955 — Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.Phase 4Recruiting100Well- Konnect Healthcare Services and Research Firm2024-03-01
NCT05808400 — Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19Early Phase 1Unknown80Huazhong University of Science and Technology2023-02-15
NCT05126563 — Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 SyndromePhase 2Completed79Hope Biosciences Research Foundation2022-02-02
NCT06492798 — Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID PatientsPhase 1, Phase 2Recruiting76Changhai Hospital2023-09-01
NCT05669261 — Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 InfectionPhase 1Unknown20American CryoStem Corporation2023-08-01
NCT06156241 — Stem Cell Study for Long COVID-19 Neurological SymptomsPhase 1Unknown12Charles Cox2024-01

Most recently registered

StudyPhaseStatusPlanned nLead sponsorStart
NCT05116761 — ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndromen/aWithdrawnn/aDirect Biologics, LLC2024-11
NCT06441955 — Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.n/aRecruitingn/aWell- Konnect Healthcare Services and Research Firm2024-03-01
NCT06156241 — Stem Cell Study for Long COVID-19 Neurological Symptomsn/aUnknownn/aCharles Cox2024-01
NCT06492798 — Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patientsn/aRecruitingn/aChanghai Hospital2023-09-01
NCT05669261 — Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infectionn/aUnknownn/aAmerican CryoStem Corporation2023-08-01

Reading this honestly

A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found. For Long COVID specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.

Frequently asked

How many stem-cell trials exist for Long COVID?

10 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 2 were recruiting.

Which therapy class is furthest along for Long COVID?

Ranked by Phase 3/4 records: MSC (0), HSCT (0), exosomes (0), PRP (0).

Does a recruiting trial mean I can be treated?

No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads

Download the query data

Download CSV · Download JSON

Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.